Scholarlink

<p>Novel therapeutic targets for renal protection are imperative due to the escalating prevalence of end-stage kidney disease despite existing treatments for chronic kidney disease (CKD). We explored the reno-protective effects of D-serine and D-alanine, which have previously demonstrated efficacy in acute kidney injury against CKD. Female and male 5/6-nephrectomy mice were used as CKD models, receiving 20 mM D-serine or D-alanine supplementation, and their survival rates, renal function, and transcriptomic changes were examined. The proliferation of human tubular epithelial cells supplemented with D-serine or D-alanine was evaluated in vitro. A prospective cohort study involving 14 patients was conducted to examine the association between increased blood D-serine or D-alanine levels and long-term renal function decline. D-serine or D-alanine supplementation improved survival rates and renal function in female 5/6-nephrectomy mice. D-alanine supplementation was associated with the upregulation of mitochondrial pathway-related genes. Long-term supplementation (500 days) in normal mice did not induce nephrotoxicity, and promoted tubular epithelial cell proliferation. Although a trend toward a slower decline in eGFR was observed in patients with higher D-alanine levels, this association was limited and does not indicate a causal relationship. Further studies involving D-Ala interventions in patients with CKD are needed to confirm these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

D-serine and D-alanine supplementation protects against chronic kidney disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月11日

查看全文
  • Yusuke Nakade,
  • Yasunori Iwata,
  • Tadashi Toyama,
  • Taku Kobayashi,
  • Masashi Mita,
  • Yuta Yamamura,
  • Megumi Oshima,
  • Toshiaki Tokumaru,
  • Shinji Kitajima,
  • Miho Shimizu,
  • Norihiko Sakai,
  • Takashi Wada

摘要

Novel therapeutic targets for renal protection are imperative due to the escalating prevalence of end-stage kidney disease despite existing treatments for chronic kidney disease (CKD). We explored the reno-protective effects of D-serine and D-alanine, which have previously demonstrated efficacy in acute kidney injury against CKD. Female and male 5/6-nephrectomy mice were used as CKD models, receiving 20 mM D-serine or D-alanine supplementation, and their survival rates, renal function, and transcriptomic changes were examined. The proliferation of human tubular epithelial cells supplemented with D-serine or D-alanine was evaluated in vitro. A prospective cohort study involving 14 patients was conducted to examine the association between increased blood D-serine or D-alanine levels and long-term renal function decline. D-serine or D-alanine supplementation improved survival rates and renal function in female 5/6-nephrectomy mice. D-alanine supplementation was associated with the upregulation of mitochondrial pathway-related genes. Long-term supplementation (500 days) in normal mice did not induce nephrotoxicity, and promoted tubular epithelial cell proliferation. Although a trend toward a slower decline in eGFR was observed in patients with higher D-alanine levels, this association was limited and does not indicate a causal relationship. Further studies involving D-Ala interventions in patients with CKD are needed to confirm these findings.